Jan Frenking

Statistics

Publications

Citations

213

H-Index

Active since

2024

Affiliations

Universitätsklinikum Würzburg(Current)

Heidelberg University

University Hospital Heidelberg

German Cancer Research Center

National Center for Tumor Diseases

Jan Frenking is an author at Universitätsklinikum Würzburg specializing in multiple myeloma treatment, refractory multiple myeloma, and multiple myeloma therapy.

ORCID

Publications per year

2024–2025

Publications

Real-world analysis of teclistamab in 123 RRMM patients from Germany

Christine Riedhammer, Florian Bassermann, Britta Besemer et al. · Leukemia · 2024 · 104 citations · Full text

Medicine, Pathology, Molecular Pathology +2

EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myeloma

Jan Frenking, Xiang Zhou, Thomas Hielscher et al. · Journal for ImmunoTherapy of Cancer · 2024 · 40 citations · Full text

Life Sciences, Immunology, Oncology +17

Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial

Marc S. Raab, Niels Weinhold, K. Martin Kortüm et al. · Blood · 2024 · 40 citations

Medicine, Immunology, Oncology +15

A German multicenter real‐world analysis of talquetamab in 138 patients with relapsed/refractory multiple myeloma

Jan Frenking, Christine Riedhammer, Raphael Teipel et al. · HemaSphere · 2025 · 18 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Bridging intensity is associated with impaired hematopoietic recovery after BCMA CAR-T therapy for multiple myeloma

Jan Frenking, Xiang Zhou, Kai Rejeski et al. · Blood Advances · 2025 · 11 citations · Full text

Medicine, Hematology, Immunology +17

1–5 of 5